Stay updated with breaking news from Evaluate Efficacy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three presentations on amyotrophic lateral sclerosis (ALS) as part of the 2023...
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present more than 20 abstracts, including one late-breaking presentation during the 2023 American...
A total of 24 accepted abstracts, including six oral and digital oral presentations, reinforce AbbVie's commitment to research that helps advance standards of...
Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult paroxysmal nocturnal hemoglobinuria (PNH) patients
Phase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for iptacopan in...